A myeloperoxidase antibody (MPO) test with a result of 0.2 likely refers to a quantitative measurement, possibly expressed in units per milliliter or a similar concentration unit. This serological test detects autoantibodies targeting myeloperoxidase, an enzyme primarily found in neutrophils, a type of white blood cell. These autoantibodies are associated with certain autoimmune vasculitides, particularly microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome. A value of 0.2 suggests a very low level of these antibodies, potentially indicating a negative or borderline result, depending on the specific assay and reference range used by the testing laboratory. A proper interpretation requires comparing the numerical result with the laboratory’s established reference interval.
Accurate detection of circulating MPO autoantibodies is crucial for diagnosing and managing these vasculitides. These conditions can affect small to medium-sized blood vessels in various organs, leading to serious complications if left untreated. The presence of MPO autoantibodies, often in conjunction with clinical symptoms and other laboratory findings, aids clinicians in distinguishing these vasculitides from other conditions with similar presentations. This distinction allows for timely intervention and appropriate treatment strategies, ultimately improving patient outcomes. The development of standardized assays for MPO antibody detection has significantly improved diagnostic accuracy in recent decades.
